MX2012007813A - Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional. - Google Patents

Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.

Info

Publication number
MX2012007813A
MX2012007813A MX2012007813A MX2012007813A MX2012007813A MX 2012007813 A MX2012007813 A MX 2012007813A MX 2012007813 A MX2012007813 A MX 2012007813A MX 2012007813 A MX2012007813 A MX 2012007813A MX 2012007813 A MX2012007813 A MX 2012007813A
Authority
MX
Mexico
Prior art keywords
additional active
treatment
combination
active agent
sleep apnea
Prior art date
Application number
MX2012007813A
Other languages
English (en)
Inventor
Thomas Najarian
Leland Wilson
Peter Tam
Charles H Bowden
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012007813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vivus Inc filed Critical Vivus Inc
Publication of MX2012007813A publication Critical patent/MX2012007813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se relaciona generalmente a métodos y formulaciones farmacéuticas útiles en el tratamiento de pacientes que sufren del síndrome de apnea obstructiva del sueño (OSAS). El tratamiento del OSAS se efectúa al administrar un inhibidor de anhidrasa carbónica al paciente en combinación con por lo menos un agente activo adicional. Ejemplos de agentes activos adicionales incluyen modafinilo, eszopiclona, Zolpidem, zaleplón y fentermina.
MX2012007813A 2010-01-07 2011-01-07 Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional. MX2012007813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29312910P 2010-01-07 2010-01-07
PCT/US2011/020588 WO2011085256A2 (en) 2010-01-07 2011-01-07 Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent

Publications (1)

Publication Number Publication Date
MX2012007813A true MX2012007813A (es) 2012-08-01

Family

ID=44306177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007813A MX2012007813A (es) 2010-01-07 2011-01-07 Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.

Country Status (13)

Country Link
US (3) US20110224196A1 (es)
EP (1) EP2521546A4 (es)
JP (1) JP2013516488A (es)
KR (1) KR20120101588A (es)
CN (1) CN102781446A (es)
AU (1) AU2011203970A1 (es)
BR (1) BR112012016799A2 (es)
CA (1) CA2786026A1 (es)
CL (1) CL2012001844A1 (es)
IL (1) IL220552A0 (es)
IN (1) IN2012DN06616A (es)
MX (1) MX2012007813A (es)
WO (1) WO2011085256A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3179999A2 (en) * 2014-08-14 2017-06-21 Vivus, Inc. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
US20160367503A1 (en) * 2015-06-20 2016-12-22 Cary Erwin Fechter Combination Medication for Neuro-Degenerative Diseases
JP6930969B2 (ja) 2015-07-08 2021-09-01 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
ES2817582T3 (es) 2016-05-11 2021-04-07 Jan Hedner Sultiame para el tratamiento de la apnea del sueño
US20210213001A1 (en) * 2018-09-06 2021-07-15 Ian COOKE Method of treating a sleep breathing disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021A (en) * 1847-03-20 Jambs haworth
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2706767B1 (es) * 1993-06-22 1995-09-08 Lafon Labor
DE60019904T2 (de) * 1999-02-24 2006-05-04 University Of Cincinnati, Cincinnati Verwendung von sulfamatderivaten zur behandlung von impulskontrollerkrankungen
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US20040229943A1 (en) * 2003-05-16 2004-11-18 Cephalon Inc Analeptic and drug combinations
EP1516869A1 (en) * 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1691811B1 (en) * 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
SE0400378D0 (sv) * 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20060039867A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
EP1833467B1 (en) * 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
JP2009508854A (ja) * 2005-09-16 2009-03-05 セリューサイエンス アーベー 睡眠時呼吸障害の予防及び治療方法及び手段
CA2673481A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
EP2142183A2 (en) * 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
CA2688430A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders

Also Published As

Publication number Publication date
WO2011085256A3 (en) 2011-11-03
US20150231110A1 (en) 2015-08-20
US20110224196A1 (en) 2011-09-15
US20140094511A1 (en) 2014-04-03
IL220552A0 (en) 2012-08-30
KR20120101588A (ko) 2012-09-13
CA2786026A1 (en) 2011-07-14
AU2011203970A1 (en) 2012-07-12
JP2013516488A (ja) 2013-05-13
IN2012DN06616A (es) 2015-10-23
EP2521546A2 (en) 2012-11-14
CL2012001844A1 (es) 2013-03-22
WO2011085256A2 (en) 2011-07-14
EP2521546A4 (en) 2013-06-26
BR112012016799A2 (pt) 2019-10-08
CN102781446A (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
MX2012007813A (es) Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.
PH12013501790B1 (en) Use of dpp iv inhibitors
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
EA201390827A1 (ru) Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом
WO2011041632A3 (en) Combination therapies for the treatment of obesity
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
NZ602510A (en) Treatment of lupus nephritis using laquinimod
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
WO2010151565A3 (en) Combination therapies for the treatment of obesity
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2010045417A3 (en) Combination therapies for the treatment of obesity
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
MX2013004873A (es) Metodos y composiciones para tratar diarrea asociada con vih.
WO2010151503A3 (en) Combination therapies for the treatment of obesity
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.